|
(Alliance News) - GlaxoSmithKline PLC on Wednesday said alongside Paris-based pharmaceutical giant Sanofi SA, it plans to submit data for both the booster and phase three efficacy trials as the base of regulatory applications for their Covid-19 vaccine.
In the VAT02 booster trial, final analysis confirmed its universal ability to boost antibodies 18-to-30-fold across vaccine platforms, including mRNA and adenovirus vaccines.
Also, in the VAT08 phase three primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations showed full efficacy against severe Covid-19 disease and hospitalisation.
The vaccine demonstrated 75% efficacy against moderate or severe Covid-19, and 58% efficacy against any symptomatic Covid-19, in line with current expected vaccine effectiveness including variants of concern.
Brentford, England-based Glaxo and Sanofi are currently in talks with several regulatory authorities, including the US Food & Drug Authorization and European Medicines Agency.
"The evolving epidemiology of Covid-19 demonstrates the need for a variety of vaccines. Our adjuvanted protein-based vaccine candidate uses a well-established approach that has been applied widely to prevent infection with other viruses including pandemic flu. We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period," said Roger Connor, president of GSK Vaccines.
Shares in GlaxoSmithKline were up 1.2% at 1,575.47 pence on Wednesday in London, while Sanofi's shares were 1.3% higher at EUR93.26 in Paris.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
